Use of medicines in pregnancy and breastfeeding

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued comprehensive guidance to manage the use of medications during pregnancy and breastfeeding. As a regulatory framework document rather than a specific site inspection report, it outlines safety standards for healthcare providers and developers. The document highlights critical risks associated with drugs like sodium valproate and oral retinoids, which can lead to birth defects or developmental issues, particularly during the first trimester. Operating under the framework of CHMP Guidelines and ICH-S5 standards, the MHRA requires the implementation of Pregnancy Prevention Programmes (PPP) for high-risk medications. These programs necessitate formal agreements between patients and clinicians, ensuring that risks are understood and effective contraception is utilized. Required actions for healthcare professionals include conducting regular pregnancy testing and reporting any adverse outcomes through the Yellow Card scheme. Additionally, the MHRA has formed the Safer Medicines in Pregnancy and Breastfeeding Information Consortium to provide consistent advice across the NHS. Developers are encouraged to use pharmacokinetic modeling to ensure appropriate dosing, while patients are advised never to stop prescribed treatments without professional consultation to balance maternal health needs with fetal safety.